鲁抗医药(600789.SH)：阿瑞匹坦获得化学原料药上市申请批准通知书

智通财经17:18

智通财经APP讯，鲁抗医药(600789.SH)发布公告，近日，公司收到国家药品监督管理局颁发的关于阿瑞匹坦的《化学原料药上市申请批准通知书》(通知书编号：2026YS00559)，该药品批准上市申请。

阿瑞匹坦是人P物质神经激肽1(NK1)受体的选择性高亲合力拮抗剂，与其它止吐药物联合给药，适用于预防高度致吐性抗肿瘤化疗的初次和重复治疗过程中出现的急性和迟发性恶心和呕吐。对其他现有治疗化疗引起恶心呕吐(CINV)和术后恶心呕吐(PONV)的药物的作用靶点5-羟色胺受体3(5-HT3)、多巴胺受体和糖皮质激素受体的亲和力低或无亲和力。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2645028423?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-22 17:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645028423","market":"sh","top_or_hot":-1,"title":"鲁抗医药(600789.SH)：阿瑞匹坦获得化学原料药上市申请批准通知书","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/600789\">鲁抗医药</a>(600789.SH)发布公告，近日，公司收到国家药品监督管理局颁发的关于阿瑞匹坦的《化学原料药上市申请批准通知书》(通知书编号：2026YS00559)，该药品批准上市申请。</p><p>阿瑞匹坦是人P物质神经激肽1(NK1)受体的选择性高亲合力拮抗剂，与其它止吐药物联合给药，适用于预防高度致吐性抗肿瘤化疗的初次和重复治疗过程中出现的急性和迟发性恶心和呕吐。对其他现有治疗化疗引起恶心呕吐(CINV)和术后恶心呕吐(PONV)的药物的作用靶点5-羟色胺受体3(5-HT3)、多巴胺受体和糖皮质激素受体的亲和力低或无亲和力。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>鲁抗医药(600789.SH)：阿瑞匹坦获得化学原料药上市申请批准通知书</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n鲁抗医药(600789.SH)：阿瑞匹坦获得化学原料药上市申请批准通知书\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/600789\">鲁抗医药</a>(600789.SH)发布公告，近日，公司收到国家药品监督管理局颁发的关于阿瑞匹坦的《化学原料药上市申请批准通知书》(通知书编号：2026YS00559)，该药品批准上市申请。</p><p>阿瑞匹坦是人P物质神经激肽1(NK1)受体的选择性高亲合力拮抗剂，与其它止吐药物联合给药，适用于预防高度致吐性抗肿瘤化疗的初次和重复治疗过程中出现的急性和迟发性恶心和呕吐。对其他现有治疗化疗引起恶心呕吐(CINV)和术后恶心呕吐(PONV)的药物的作用靶点5-羟色胺受体3(5-HT3)、多巴胺受体和糖皮质激素受体的亲和力低或无亲和力。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1456930.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600789","symbol_name":"鲁抗医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1456930.html","article_id":"2645028423","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645028423","pubTimestamp":1782119934,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，鲁抗医药(600789.SH)发布公告，近日，公司收到国家药品监督管理局颁发的关于阿瑞匹坦的《化学原料药上市申请批准通知书》(通知书编号：2026YS00559)，该药品批准上市申请。阿瑞匹坦是人P物质神经激肽1(NK1)受体的选择性高亲合力拮抗剂，与其它止吐药物联合给药，适用于预防高度致吐性抗肿瘤化疗的初次和重复治疗过程中出现的急性和迟发性恶心和呕吐。对其他现有治疗化疗引起恶心呕吐(CINV)和术后恶心呕吐(PONV)的药物的作用靶点5-羟色胺受体3(5-HT3)、多巴胺受体和糖皮质激素受体的亲和力低或无亲和力。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600789":"鲁抗医药","BK0188":"融资融券","BK0168":"禽流感","BK0046":"生物疫苗","IPOS":"Renaissance International IPO ETF","BK0239":"医药制造"},"translate_title":"Lukang Pharmaceutical (600789.SH): Aprepitant obtained the notice of approval for chemical API marketing application","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600789":1.5,"IPOS":1.5},"content_text":"智通财经APP讯，鲁抗医药(600789.SH)发布公告，近日，公司收到国家药品监督管理局颁发的关于阿瑞匹坦的《化学原料药上市申请批准通知书》(通知书编号：2026YS00559)，该药品批准上市申请。阿瑞匹坦是人P物质神经激肽1(NK1)受体的选择性高亲合力拮抗剂，与其它止吐药物联合给药，适用于预防高度致吐性抗肿瘤化疗的初次和重复治疗过程中出现的急性和迟发性恶心和呕吐。对其他现有治疗化疗引起恶心呕吐(CINV)和术后恶心呕吐(PONV)的药物的作用靶点5-羟色胺受体3(5-HT3)、多巴胺受体和糖皮质激素受体的亲和力低或无亲和力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645028423","isCrawlerRequest":true}